Investor List:

Top Therapeutics Seed Investors (354)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Therapeutics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Alex Davidov, General Partner at Abstract Ventures
Alex Davidov
Abstract Ventures·General Partner
Sweet spot: $500K
Range: $250K - $750K
Investors in San Francisco (CA)
Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Cybersecurity (Pre-seed), Investors in Cybersecurity (Pre-seed), Investors in Insurance (Pre-seed), Investors in Insurance (Pre-seed), Investors in Web3/Crypto (Pre-seed), Investors in Web3/Blockchain (Pre-seed), Investors in BioTech (Pre-seed), Investors in Web3/Crypto (Pre-seed), Investors in BioTech (Pre-seed), Investors in Web3/Blockchain (Pre-seed), Investors in FinTech (Pre-seed), Investors in SaaS (Pre-seed), Investors in FinTech (Pre-seed), Investors in SaaS (Pre-seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Cybersecurity (Seed), Investors in Cybersecurity (Seed), Investors in Insurance (Seed), Investors in Insurance (Seed), Investors in Web3/Blockchain (Seed), Investors in Web3/Crypto (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Web3/Crypto (Seed), Investors in Web3/Blockchain (Seed), Investors in FinTech (Seed), Investors in SaaS (Seed), Investors in FinTech (Seed), Investors in SaaS (Seed), Investors in Angel, Scout, and Solo-Capitalists (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Josh Wolfe, Managing Partner at Lux Capital
Josh Wolfe
Lux Capital·Managing Partner
Sweet spot: $10.0M
Range: $1M - $50.0M
Investors in New York (NY), Investors in Menlo Park (CA)
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Manufacturing (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Manufacturing (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Manufacturing (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Los Angeles / Southern California (Other Lists), Investors in Boston / New England (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Dave Morin, Managing Partner at Offline Ventures
Dave Morin
Offline Ventures·Managing Partner
Sweet spot: $1M
Range: $500K - $5.0M
Investors in SF Bay Area (CA), Investors in California
Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Space (Pre-seed), Investors in Space (Pre-seed), Investors in EnergyTech (Pre-seed), Investors in Robotics (Pre-seed), Investors in EnergyTech (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Web3/Crypto (Pre-seed), Investors in Robotics (Pre-seed), Investors in BioTech (Pre-seed), Investors in Social Networks (Pre-seed), Investors in BioTech (Pre-seed), Investors in Social Networks (Pre-seed), Investors in Web3/Crypto (Pre-seed), Investors in Consumer Internet (Pre-seed), Investors in AI (Pre-seed), Investors in Consumer Internet (Pre-seed), Investors in AI (Pre-seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Space (Seed), Investors in DeepTech (Seed), Investors in Space (Seed), Investors in EnergyTech (Seed), Investors in DeepTech (Seed), Investors in Robotics (Seed), Investors in EnergyTech (Seed), Investors in Robotics (Seed), Investors in Web3/Crypto (Seed), Investors in BioTech (Seed), Investors in Social Networks (Seed), Investors in Social Networks (Seed), Investors in BioTech (Seed), Investors in Web3/Crypto (Seed), Investors in AI (Seed), Investors in Consumer Internet (Seed), Investors in AI (Seed), Investors in Consumer Internet (Seed), Investors in Investors who were founders (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in Angel, Scout, and Solo-Capitalists (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of James C. Murray, Partner at ExSight Capital Management
James C. Murray
Sweet spot: $1M
Range: $200K - $4.0M
Investors in Europe, Investors in Canada, Investors in United States
Investors in Diagnostics (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Drug Delivery (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Hardware (Pre-seed), Investors in Robotics (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Drug Delivery (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Hardware (Pre-seed), Investors in Robotics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in BioTech (Pre-seed), Investors in Therapeutics (Seed), Investors in Drug Delivery (Seed), Investors in Diagnostics (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Health & Hospital Services (Seed), Investors in Digital Health (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Hardware (Seed), Investors in Robotics (Seed), Investors in Drug Delivery (Seed), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Hardware (Seed), Investors in Robotics (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Digital Health (Series A), Investors in Diagnostics (Series A), Investors in Drug Delivery (Series A), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Medical Devices (Series A), Investors in Hardware (Series A), Investors in Diagnostics (Series A), Investors in Robotics (Series A), Investors in Health & Hospital Services (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in Drug Delivery (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Hardware (Series A), Investors in Robotics (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Hardware (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Digital Health (Series B), Investors in Drug Delivery (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Therapeutics (Series B), Investors in Robotics (Series B), Investors in Drug Delivery (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Hardware (Series B), Investors in Robotics (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Canada (Other Lists), Investors in Investors who were founders (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in New York City (Other Lists)
Photo of Alexander Hall-Daniels, Associate at IndieBio
Alexander Hall-Daniels
IndieBio·Associate
Sweet spot: $525K
Range: $275K - $525K
Investors in United States, Investors in New York
Photo of David Singer, Managing Partner at Maverick Capital
David Singer
Maverick Capital·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Francisco (CA)
Photo of Johnny Hu, Principal at Menlo Ventures
Johnny Hu
Menlo Ventures·Principal
Sweet spot: $12.0M
Range: $8.0M - $15.0M
Investors in SF Bay Area (CA), Investors in San Francisco (CA)
Get new data & insights delivered to your inbox
Firms investing in this space